Albert David growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
−3.5%−4.6%+6.1%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+80.6%−93.5%+5.7%
−9.0%−109.8%+11.9%
−108.7%−77.2%+108.5%
−108.7%−77.2%+108.5%
+1.5%+2.7%+17.6%
−0.2%+2.5%+22.9%
+73.1%−162.5%+332.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

ALBERTDAVD₹767.95

Albert David Limited

· Pharma & Health
₹ CrorePeersVALIANTLABHALEOSLABSZIMLABMEDICOMEDICAMEQANUHPHRAHCLWANBURYMcap ₹438 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+6.1-4.6-3.5—
EBITDA Growth—+5.7-93.5+80.6—
EBIT Growth—+11.9-109.8-9.0—
Net Income Growth—+108.5-77.2-108.7—
EPS Growth—+108.5-77.2-108.7—
Total Assets Growth—+17.6+2.7+1.5—
Total Equity Growth—+22.9+2.5-0.2—
Cash from Operations Growth—+332.7-162.5+73.1—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.